

Mark A Preston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11567454/publications.pdf>

Version: 2024-02-01

116
papers

2,898
citations

159358

30
h-index

182168

51
g-index

117
all docs

117
docs citations

117
times ranked

4795
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Association between Operative Time and Short-Term Radical Cystectomy Complications. <i>Urologia Internationalis</i> , 2023, 107, 273-279. | 0.6 | 2 |
| 2 | Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473. | 0.9 | 12 |
| 3 | Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 485-485. | 0.8 | 0 |
| 4 | Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528. | 0.8 | 7 |
| 5 | 5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , . | 1.1 | 3 |
| 6 | Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).. <i>Journal of Clinical Oncology</i> , 2022, 40, e17051-e17051. | 0.8 | 0 |
| 7 | Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. <i>European Urology</i> , 2022, 82, 247-251. | 0.9 | 8 |
| 8 | Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5111-TPS5111. | 0.8 | 0 |
| 9 | Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies. <i>Cancer Research</i> , 2022, 82, 5893-5893. | 0.4 | 0 |
| 10 | Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 432-432. | 0.8 | 0 |
| 11 | Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467. | 0.8 | 4 |
| 12 | A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, 32-32. | 0.8 | 2 |
| 13 | A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. <i>Journal of Clinical Oncology</i> , 2021, 39, e17003-e17003. | 0.8 | 0 |
| 14 | Reply by Authors. <i>Journal of Urology</i> , 2021, 206, 61-61. | 0.2 | 2 |
| 15 | A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61. | 0.2 | 180 |
| 16 | Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214. | 0.5 | 3 |
| 17 | Is Vasectomy a Cause of Prostate Cancer?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 5-6. | 3.0 | 2 |
| 18 | Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 74-80. | 1.6 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563. | 2.9 | 59 |
| 20 | AUTHOR REPLY. <i>Urology</i> , 2020, 140, 121. | 0.5 | 0 |
| 21 | The association of diabetes with risk of prostate cancer defined by clinical and molecular features. <i>British Journal of Cancer</i> , 2020, 123, 657-665. | 2.9 | 31 |
| 22 | Delayed blood transfusion is associated with mortality following radical cystectomy. <i>Scandinavian Journal of Urology</i> , 2020, 54, 290-296. | 0.6 | 1 |
| 23 | Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020, 78, 637-639. | 0.9 | 5 |
| 24 | Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 140, 115-121. | 0.5 | 6 |
| 25 | Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5503-5503. | 0.8 | 7 |
| 26 | Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439. | 0.8 | 101 |
| 27 | Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507. | 0.8 | 12 |
| 28 | A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9-9. | 0.8 | 10 |
| 29 | Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19390-e19390. | 0.8 | 0 |
| 30 | Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 540-540. | 0.8 | 0 |
| 31 | 5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. <i>Journal of Clinical Oncology</i> , 2020, 38, 39-39. | 0.8 | 0 |
| 32 | Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. <i>Journal of Clinical Oncology</i> , 2020, 38, 280-280. | 0.8 | 0 |
| 33 | Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 474-474. | 0.8 | 0 |
| 34 | Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598. | 1.4 | 27 |
| 35 | Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e488-e493. | 0.9 | 11 |
| 36 | Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. <i>European Urology Oncology</i> , 2019, 2, 126-134. | 2.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , 2019, 2, 349-354. | 2.6 | 6 |
| 38 | Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407. | 0.9 | 43 |
| 39 | Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. <i>European Urology</i> , 2019, 75, 649-658. | 0.9 | 82 |
| 40 | Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065. | 1.2 | 40 |
| 41 | Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329. | 2.0 | 20 |
| 42 | Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46. | 1.3 | 17 |
| 43 | Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019, 201, 721-727. | 0.2 | 15 |
| 44 | Diagnostic performance of ¹⁸ F-DCFPyL in the OSPREY Trial: A prospective phase 2/3 multicenter study of ¹⁸ F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5012-5012. | 0.8 | 3 |
| 45 | Genomic profiling of variant urinary tract tumor histologies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 450-450. | 0.8 | 0 |
| 46 | Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience.. <i>Journal of Clinical Oncology</i> , 2019, 37, e16037-e16037. | 0.8 | 0 |
| 47 | Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. <i>Diabetes Care</i> , 2018, 41, 1432-1437. | 4.3 | 43 |
| 48 | The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17. | 0.8 | 21 |
| 49 | Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70.. <i>European Urology</i> , 2018, 73, e96-e97. | 0.9 | 0 |
| 50 | Bladder cancer local staging: multiparametric MRI performance following transurethral resection. <i>Abdominal Radiology</i> , 2018, 43, 2412-2423. | 1.0 | 22 |
| 51 | Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270. | 0.9 | 20 |
| 52 | Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436. | 1.3 | 30 |
| 53 | Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab. <i>European Urology</i> , 2018, 73, 372-373. | 0.9 | 5 |
| 54 | Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139. | 0.9 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>Eur Urol</i> 2018;73:262-70. <i>European Urology</i> , 2018, 73, e100-e101. | 0.9 | 1 |
| 56 | Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382. | 0.9 | 62 |
| 57 | Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. <i>JCO Precision Oncology</i> , 2018, 2, 1-11. | 1.5 | 2 |
| 58 | Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 979-982. | 1.1 | 13 |
| 59 | Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. <i>Canadian Urological Association Journal</i> , 2018, 13, 32-37. | 0.3 | 2 |
| 60 | Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774. | 1.2 | 12 |
| 61 | Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , 2018, 1, 83-90. | 2.6 | 59 |
| 62 | A prospective phase 2/3 multicenter study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPREY).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5092-TPS5092. | 0.8 | 4 |
| 63 | Statin use and risk of renal cell carcinoma in three prospective cohort studies.. <i>Journal of Clinical Oncology</i> , 2018, 36, 679-679. | 0.8 | 0 |
| 64 | Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.. <i>Journal of Clinical Oncology</i> , 2018, 36, 677-677. | 0.8 | 0 |
| 65 | The prognostic impact of a negative confirmatory biopsy in men on active surveillance for prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 76-76. | 0.8 | 0 |
| 66 | FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. <i>Journal of Clinical Oncology</i> , 2018, 36, 465-465. | 0.8 | 0 |
| 67 | The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 492-492. | 0.8 | 0 |
| 68 | Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4539-4539. | 0.8 | 0 |
| 69 | Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 852-860. | 0.8 | 104 |
| 70 | Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. <i>Journal of Urology</i> , 2017, 198, 297-304. | 0.2 | 35 |
| 71 | Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study. <i>European Urology</i> , 2017, 72, 821-827. | 0.9 | 44 |
| 72 | Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487. | 0.9 | 110 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724. | 5.8 | 106 |
| 74 | Editorial Comment. <i>Journal of Urology</i> , 2017, 197, 1075-1075. | 0.2 | 0 |
| 75 | Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355. | 2.0 | 138 |
| 76 | Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754. | 0.9 | 39 |
| 77 | Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 305-305. | 0.8 | 63 |
| 78 | Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, 332-332. | 0.8 | 1 |
| 79 | Post-orchietomy adjuvant therapy versus surveillance for stage IS testicular cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 406-406. | 0.8 | 0 |
| 80 | Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 331-331. | 0.8 | 0 |
| 81 | Characterizing the costs of complications after cystectomy: Can we target the primary drivers?. <i>Journal of Clinical Oncology</i> , 2017, 35, 304-304. | 0.8 | 0 |
| 82 | Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16001-e16001. | 0.8 | 0 |
| 83 | Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , 2016, 118, 286-297. | 1.3 | 39 |
| 84 | Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663. | 0.8 | 174 |
| 85 | Moving Towards Widespread Implementation of Enhanced Recovery Protocols for Radical Cystectomy. <i>European Urology</i> , 2016, 70, 1004-1005. | 0.9 | 1 |
| 86 | Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. <i>Cancer Prevention Research</i> , 2016, 9, 933-941. | 0.7 | 18 |
| 87 | Patterns of Recurrence in Upper Tract Transitional Cell Carcinoma: Imaging Surveillance. <i>American Journal of Roentgenology</i> , 2016, 207, 789-796. | 1.0 | 6 |
| 88 | Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536. | 0.8 | 70 |
| 89 | Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711. | 0.8 | 74 |
| 90 | Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. <i>European Urology</i> , 2016, 70, 837-845. | 0.9 | 178 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. <i>Journal of Urology</i> , 2016, 195, 399-405. | 0.2 | 8 |
| 92 | Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. <i>JAMA Oncology</i> , 2016, 2, 500. | 3.4 | 94 |
| 93 | The impact of histological variants on bladder cancer survival: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 458-458. | 0.8 | 1 |
| 94 | Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 306-306. | 0.8 | 0 |
| 95 | Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 588-588. | 0.8 | 0 |
| 96 | Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 442-442. | 0.8 | 0 |
| 97 | Diagnosis of Bladder Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 677-685. | 0.7 | 17 |
| 98 | Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 383.e9-383.e16. | 0.8 | 24 |
| 99 | New Trends in the Surgical Management of Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 253-269. | 0.9 | 9 |
| 100 | The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. <i>Journal of Surgical Education</i> , 2015, 72, 1018-1025. | 1.2 | 36 |
| 101 | Role of imaging in testicular cancer: Current and future practice. <i>Future Oncology</i> , 2015, 11, 2575-2586. | 1.1 | 17 |
| 102 | Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e9-504.e17. | 0.8 | 21 |
| 103 | The association between nerve sparing and a positive surgical margin during radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e1-18.e6. | 0.8 | 55 |
| 104 | Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. <i>Canadian Urological Association Journal</i> , 2015, 9, 207. | 0.3 | 13 |
| 105 | The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. <i>Journal of Clinical Oncology</i> , 2015, 33, 414-414. | 0.8 | 0 |
| 106 | Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. <i>Journal of Clinical Oncology</i> , 2015, 33, e17528-e17528. | 0.8 | 0 |
| 107 | Predicting the Gleason sum of a patient with a prostate biopsy core Gleason ≤ 7 and a prostate biopsy core Gleason ≥ 8 . <i>Canadian Urological Association Journal</i> , 2014, 8, 476. | 0.3 | 0 |
| 108 | 5 α -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1301. | 2.6 | 38 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 52.e19-52.e25. | 0.8 | 68 |
| 110 | Clinical features of leiomyosarcoma of the urinary bladder: Analysis of 183 cases. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 958-965. | 0.8 | 30 |
| 111 | Reply from Authors re: David Margel. Metformin to Prevent Prostate Cancer: A Call to Unite. Eur Urol 2014;66:1021-2. European Urology, 2014, 66, 1022-1023. | 0.9 | 2 |
| 112 | Positive Surgical Margins After Radical Prostatectomy: Does It Matter?. European Urology, 2014, 65, 314-315. | 0.9 | 8 |
| 113 | Metformin Use and Prostate Cancer Risk. European Urology, 2014, 66, 1012-1020. | 0.9 | 109 |
| 114 | The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. Journal of Clinical Oncology, 2014, 32, 4576-4576. | 0.8 | 4 |
| 115 | Diagnostic tests in urology: magnetic resonance imaging (<sc>MRI</sc>) for the staging of prostate cancer. BJU International, 2013, 111, 514-517. | 1.3 | 3 |
| 116 | Testicular Cancer: What the Radiologist Needs to Know. American Journal of Roentgenology, 2013, 200, 1215-1225. | 1.0 | 87 |